Cochrane · systematic review · CD012158
Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
van Agteren, JEM, Hnin, K, Grosser, D, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
37
No studies
5
Included studies
NR
No studies 5 · 11.9%Ungraded 0 · 0%Very low 0 · 0%Low 11 · 26.2%Moderate 17 · 40.5%High 9 · 21.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
AeriSeal versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline in FEV1 AeriSeal vs control | no estimate extracted | 1 study · 34 participants | Low Downgraded: imprecision |
Mortality at end of AeriSeal vs control | OR 2.9 [0.14, 62.15] | 1 study · 95 participants | Low Downgraded: risk of bias, imprecision |
Units SGRQ change from baseline AeriSeal vs control | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Change from baseline in lung function parameters other than FEV1 AeriSeal vs control | no estimate extracted | NR | No studies |
Meters change from baseline in 6MWD AeriSeal vs control | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Adverse events at end of AeriSeal vs control | OR 3.71 [1.34, 10.24] | 1 study · 95 participants | Moderate Downgraded: risk of bias, imprecision |
Cost effectiveness end of AeriSeal vs control | no estimate extracted | NR | No studies |
Airway bypass stents versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% Change from baseline in FEV1 Airway bypass stents vs control | no estimate extracted | 1 study · 350 participants | High |
Mortality at end of Airway bypass stents vs control | OR 0.76 [0.21, 2.77] | 1 study · 350 participants | Moderate Downgraded: imprecision |
Units SGRQ at end of Airway bypass stents vs control | no estimate extracted | 1 study · 350 participants | High |
Change from baseline in lung function parameters other than FEV1 Airway bypass stents vs control | no estimate extracted | 1 study · 350 participants | High |
Meters 6MWD at end of Airway bypass stents vs control | no estimate extracted | 1 study · 350 participants | Moderate Downgraded: imprecision |
Adverse events at end of Airway bypass stents vs control | OR 1.33 [0.65, 2.73] | 1 study · 315 participants | Moderate Downgraded: imprecision |
Cost effectiveness Airway bypass stents vs control | no estimate extracted | NR | No studies |
Endobronchial coils versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline in FEV1 Endobronchial coils vs control | no estimate extracted | 2 studies · 146 participants | Moderate Downgraded: imprecision |
Mortality at end of Endobronchial coils vs control | OR 1.49 [0.67, 3.29] | 3 studies · 461 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Units SGRQ change from baseline Endobronchial coils vs control | no estimate extracted | 3 studies · 461 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Change from baseline in lung function parameters other than FEV1 Endobronchial coils vs control | no estimate extracted | 3 studies · 461 participants | High |
Meters change from baseline in 6MWD Endobronchial coils vs control | no estimate extracted | 3 studies · 461 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events at end of Endobronchial coils vs control | OR 2.14 [1.41, 3.23] | 3 studies · 461 participants | High |
Cost effectiveness at end of Endobronchial coils vs control | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Endobronchial valves versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline in FEV1 Endobronchial valves vs control | no estimate extracted | 5 studies · 703 participants | Low Downgraded: imprecision, inconsistency |
Mortality at end of Endobronchial valves vs control | OR 1.07 [0.47, 2.43] | 5 studies · 703 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Units of SGRQ change from baseline Endobronchial valves vs control | no estimate extracted | 5 studies · 695 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Change from baseline in lung function parameters other than FEV1 Endobronchial valves vs control | no estimate extracted | 3 studies · 200 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Meters change from baseline in 6MWD Endobronchial valves vs control | no estimate extracted | 4 studies · 379 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events at end of Endobronchial valves vs control | OR 5.85 [2.16, 15.84] | 3 studies · 482 participants | High |
Cost‐ effectiveness Endobronchial valves vs control | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Intrabronchial valves versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline in FEV1 Intrabronchial valves vs control | no estimate extracted | 1 study · 272 participants | Moderate Downgraded: imprecision |
Mortality at end of Intrabronchial valves vs control | OR 4.95 [0.85, 28.94] | 2 studies · 350 participants | Moderate Downgraded: imprecision |
Units of SGRQ change from baseline Intrabronchial valves vs control | no estimate extracted | 2 studies · 350 participants | High |
Change from baseline in lung function parameters other than FEV1 Intrabronchial valves vs control | no estimate extracted | 2 studies · 312 participants | High |
Meters change from baseline in 6MWD Intrabronchial valves vs control | no estimate extracted | 2 studies · 316 participants | Moderate Downgraded: imprecision |
Adverse events at end of Intrabronchial valves vs control | OR 3.41 [1.48, 7.84] | 2 studies · 350 participants | High |
Cost‐ effectiveness Intrabronchial valves vs control | no estimate extracted | NR | No studies |
Vapour ablation versus control
Population: Participants suffering from chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline in FEV1 Vapour ablation vs control | no estimate extracted | 1 study · 64 participants | Moderate Downgraded: imprecision |
Mortality at end of Vapour ablation vs control | OR 2.82 [0.13, 61.06] | 1 study · 69 participants | Low Downgraded: risk of bias, imprecision |
Units of SGRQ change from baseline Vapour ablation vs control | no estimate extracted | 1 study · 65 participants | Low Downgraded: risk of bias, imprecision |
Lung function parameters other than FEV1 Vapour ablation vs control | no estimate extracted | 1 study · 69 participants | Moderate Downgraded: risk of bias, imprecision |
Meters at end of Vapour ablation vs control | no estimate extracted | 1 study · 69 participants | Low Downgraded: risk of bias, imprecision |
Adverse events at end of Vapour ablation vs control | OR 3.86 [1, 14.97] | 1 study · 69 participants | Moderate Downgraded: risk of bias, imprecision |
Cost effectiveness Vapour ablation vs control | no estimate extracted | NR | No studies |